

---

**LAB ALERT – NEW TEST****NOTIFICATION DATE: 12/18/2013**  
**EFFECTIVE DATE: 12/19/2013****ANTIBODY SCREEN WITH REFLEX TO IDENTIFICATION, PRENATAL****NEW TEST CODE:** ABSCR**NEW INTERFACE CODE:** 1004496**OLD TEST CODE TO BE DEACTIVATED:** ABSCR**OLD INTERFACE CODE TO BE DEACTIVATED:** 1003220**METHODOLOGY:** Manual Tube Method

**CLINICAL UTILITY:** Hemolytic disease of the fetus and newborn (HDFN) is a condition in which transplacental passage of maternal antibodies results in immune hemolysis of fetal/neonatal red cells. The implicated antibodies could be naturally occurring (anti A, anti B) or immune antibodies which develop following a sensitizing event like transfusion or pregnancy. The hemolytic process may result in anemia or hyperbilirubinemia or both; thereby affecting fetal/neonatal morbidity and mortality.

Before the discovery of RhoGAM, HDFN due to anti D was a significant cause of perinatal mortality. Administration of RhoGAM to Rh (D) negative women during pregnancy and shortly after the birth of D positive infants has reduced the incidence of Rh D hemolytic disease. ABO incompatibility is now the single largest cause of HDFN in the western world. Timely detection and close follow up of this condition is necessary to reduce harmful effects on the newborn.

**PERFORMED:** Monday-Friday; must be received by 12:00 PM for same day testing**COLLECTION:** Lavender top tube (EDTA) and plain red top tube

---

**SPECIMEN PREPARATION:** Transport both tubes uncentrifuged (lavender: 7 mL; Min. 3 mL).

**STABILITY (FROM COLLECTION TO INITIATION OF TESTING):** Ambient: 72 hours; Refrigerated: 1 week; Frozen: Unacceptable

**TRANSPORT:** Refrigerated

**REFERENCE RANGE:** Negative

**RESULTS REPORTED:** Screen: 1-4 days

Identification if reflexed from positive screen: an additional 3–6 days may be required to identify antibodies and to titer clinically significant antibodies detected

**CPT CODE(S):** Screen: 86850  
Identification: 86900, 86901, 86880, 86870, 86906, additional charges may apply for id and titer as required

**PERFORMING LAB:** Screen: ClearPoint  
Identification: ARUP Laboratories

**ORDER/CONTACT INFORMATION:** Thomas P. Lohmann at 972-966-7135, or med fusion Client Services: 972-966-7300/Fax: 972-966-7231



Thomas P. Lohmann, MD  
Chief Medical Officer